

Resource Summary Report

Generated by [RRID](#) on Aug 30, 2026

NCI-H661

RRID:CVCL_1577

Type: Cell Line

Proper Citation

RRID:CVCL_1577

Cell Line Information

URL: https://web.expasy.org/cellosaurus/CVCL_1577

Proper Citation: RRID:CVCL_1577

Description: Cell line NCI-H661 is a Cancer cell line with a species of origin Homo sapiens (Human)

Sex: Male

Disease: Lung large cell carcinoma

Defining Citation: [PMID:1311061](#), [PMID:8806092](#), [PMID:9649128](#), [PMID:11030152](#), [PMID:11369051](#), [PMID:18083107](#), [PMID:19472407](#), [PMID:20164919](#), [PMID:20215515](#), [PMID:20557307](#), [PMID:22460905](#), [PMID:22961666](#), [PMID:25877200](#), [PMID:25984343](#), [PMID:26589293](#), [PMID:27397505](#), [PMID:28196595](#), [PMID:29681454](#), [PMID:30894373](#), [PMID:31068700](#), [PMID:31803961](#), [PMID:31978347](#), [PMID:35839778](#)

Comments: Population: Caucasian., Part of: MD Anderson Cell Lines Project., Part of: COSMIC cell lines project., Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE)., Part of: AKT genetic alteration cell panel (ATCC TCP-1029).

Category: Cancer cell line

Organism: Homo sapiens (Human)

Name: NCI-H661

Synonyms: H661, H-661, NCIH661

Cross References: BTO:BTO_0003013, CLO:CLO_0008103, EFO:EFO_0002299, ArrayExpress:E-MTAB-38, ArrayExpress:E-MTAB-783, ArrayExpress:E-MTAB-2770, ArrayExpress:E-MTAB-3610, ATCC:HTB-183, BCRC:60125, BioSample:SAMN03471326, BioSample:SAMN10988284, cancercellines:CVCL_1577, CCRID:1101HUM-

PUMC000357, CCRID:3101HUMTCHu121, Cell_Model_Passport:SIDM01122, ChEMBL-Cells:ChEMBL3308139, ChEMBL-Targets:ChEMBL1075544, CLS:305085, Cosmic:687829, Cosmic:877410, Cosmic:903578, Cosmic:909909, Cosmic:923400, Cosmic:930610, Cosmic:933579, Cosmic:961835, Cosmic:980967, Cosmic:1006540, Cosmic:1032439, Cosmic:1146922, Cosmic:1152504, Cosmic:1219063, Cosmic:1239923, Cosmic:1995587, Cosmic:2125186, Cosmic:2560232, Cosmic:2648440, Cosmic-CLP:687829, DepMap:ACH-000853, EGA:EGAS00001000978, EGA:EGAS00001002554, GDSC:687829, GEO:GSM171884, GEO:GSM171885, GEO:GSM185870, GEO:GSM206499, GEO:GSM253359, GEO:GSM274759, GEO:GSM274760, GEO:GSM434273, GEO:GSM784198, GEO:GSM794297, GEO:GSM817077, GEO:GSM827517, GEO:GSM887441, GEO:GSM888521, GEO:GSM1670257, GEO:GSM2807231, GEO:GSM2807232, IARC_TP53:523, IARC_TP53:21411, IGRhCellID:NCIH661, IZSLER:BS TCL 218, KCB:KCB 200823YJ, LiGeA:CCLE_830, LINCS_LDP:LCL-1785, Lonza:1627, Pharmacodb:NCIH661_1127_2019, PRIDE:PXD030304, Progenetix:CVCL_1577, PubChem_Cell_line:CVCL_1577, Wikidata:Q54908098

ID: CVCL_1577

Record Creation Time: 20220427T220840+0000

Record Last Update: 20260829T234734+0000

Ratings and Alerts

No rating or validation information has been found for NCI-H661.

No alerts have been found for NCI-H661.

Data and Source Information

Source: [Cellosaurus](#)

Usage and Citation Metrics

We found 23 mentions in open access literature.

Listed below are recent publications. The full list is available at [RRID](#).

Calderon-Aparicio A, et al. (2026) S6K1 Modulates STAT3 Activation to Promote Resistance to Radiotherapy in Lung Cancer. International journal of molecular sciences, 27(4).

O'Mara M, et al. (2026) Epithelial barrier DUOX2 serves as early immune defense in intestinal pathogen control. Mucosal immunology, 19(3), 100343.

Meoni P, et al. (2026) Identification and Nonclinical Characterization of SAR444200, a Novel Anti-GPC3 NANOBODY T-cell Engager, for the Treatment of GPC3+ Solid Tumors. Molecular cancer therapeutics, 25(3), 361.

Galan-Cobo A, et al. (2025) KEAP1 and STK11/LKB1 alterations enhance vulnerability to ATR inhibition in KRAS mutant non-small cell lung cancer. *Cancer cell*, 43(8), 1530.

Tedeschi A, et al. (2025) Pan-KRAS Inhibitors BI-2493 and BI-2865 Display Potent Antitumor Activity in Tumors with KRAS Wild-type Allele Amplification. *Molecular cancer therapeutics*, 24(4), 550.

O'Mara M, et al. (2025) Spatiotemporal H₂O₂ flashes coordinate actin cytoskeletal remodeling and regulate cell migration and wound healing. *Nature communications*, 16(1), 6868.

De Rosa C, et al. (2025) DNA-PK inhibition sustains the antitumor innate immune response in small cell lung cancer. *iScience*, 28(3), 111943.

Park J, et al. (2025) MYC plus class IIa HDAC inhibition drives mitochondrial dysfunction in non-small cell lung cancer. *Cell reports*, 44(6), 115722.

De Rosa C, et al. (2024) PBMCs as Tool for Identification of Novel Immunotherapy Biomarkers in Lung Cancer. *Biomedicines*, 12(4).

Chakraborty S, et al. (2024) Lurbinectedin sensitizes PD-L1 blockade therapy by activating STING-IFN signaling in small-cell lung cancer. *Cell reports. Medicine*, 5(12), 101852.

Amato L, et al. (2024) Immune-Cell-Derived Exosomes as a Potential Novel Tool to Investigate Immune Responsiveness in SCLC Patients: A Proof-of-Concept Study. *Cancers*, 16(18).

Huang HY, et al. (2024) Incense-burning smoke ingredient Auramine enhances lincRNA-p21 expression for chemosensitization in p53-mutated non-small cell lung cancer. *Journal of hazardous materials*, 477, 135105.

Ng J, et al. (2024) Molecular and Pathologic Characterization of YAP1-Expressing Small Cell Lung Cancer Cell Lines Leads to Reclassification as SMARCA4-Deficient Malignancies. *Clinical cancer research : an official journal of the American Association for Cancer Research*, OF1.

Luo X, et al. (2022) Profiling of diverse tumor types establishes the broad utility of VHL-based ProTaCs and triages candidate ubiquitin ligases. *iScience*, 25(3), 103985.

Krall AS, et al. (2021) Asparagine couples mitochondrial respiration to ATF4 activity and tumor growth. *Cell metabolism*, 33(5), 1013.

Pearson JD, et al. (2021) Binary pan-cancer classes with distinct vulnerabilities defined by pro- or anti-cancer YAP/TEAD activity. *Cancer cell*, 39(8), 1115.

Yin M, et al. (2021) HNRNPA2B1 as a trigger of RNA switch modulates the miRNA-mediated regulation of CDK6. *iScience*, 24(11), 103345.

Caeser R, et al. (2021) MAPK pathway activation selectively inhibits ASCL1-driven small cell lung cancer. *iScience*, 24(11), 103224.

Yasui H, et al. (2021) Near-infrared photoimmunotherapy targeting GPR87: Development of a humanised anti-GPR87 mAb and therapeutic efficacy on a lung cancer mouse model. *EBioMedicine*, 67, 103372.

Pearson JD, et al. (2021) Lentiviral-mediated ectopic expression of YAP and TAZ in YAPoff cancer cell lines. *STAR protocols*, 2(4), 100870.